Board of Directors

Mats Blom

Chairman

BA, Business Administration and Economics, University of Lund and MBA, IESE University of Navarra, Barcelona, Spain

Chairman since: May 2024

Member of the Board since: April 2021

Number of shares in Egetis: 3,499,762

Number of share awards in Egetis: 112,618

Born: 1965

Other assignments: Board member of Hansa Biopharma AB and Pephexia Therapeutics ApS.

Previous experience: He has served as CFO of Zealand Pharma A/B, a biotechnology company dual listed at Nasdaq in New York and Copenhagen, and Swedish Orphan International, an orphan drug company acquired by BioVitrum in 2009. In addition, Mats has been CFO at Northsea Therapeutics, Modus Therapeutics, Active Biotech AB and Anoto Group AB. He has also served as a management consultant at Gemini Consulting and Ernst & Young.

Independent in relation to the Company’s major shareholders and the Company and its management.

Gunilla Osswald

Board Member

Pharmacist and PhD in biopharmacy and pharmacokinetics at Uppsala University, Sweden

Member of the Board since: 2017

Number of shares in Egetis: 40,000

Number of share awards in Egetis: 75,079

Born: 1961

Other current assignments: President and Chief Executive Officer of BioArctic AB. Board member of SpineMedical AB and deputy board member of LPB Sweden AB

Previous appointments: Board member of SP Process Development AB, SpineMedical Sverige AB and LPB Sweden Holding AB.

Independent in relation to the Company’s major shareholders and the Company and its management.

Behshad Sheldon

Board Member

BS in neuroscience from University of Rochester.

Member of the Board since: 2023

Number of shares in Egetis: 0

Number of share awards in Egetis: 75,079

Born: 1963

Other current assignments: Board Member, Camurus AB; Chairman of the Board of FORCE (Female Opioid Research and Clinical Experts) in Princeton, New Jersey; Board Member, Maxona Pharmaceuticals, Philadelphia, Pennsylvania; EVP & Managing Director, Biotech Value Advisors.

Previous appointments: President & CEO of Braeburn Pharmaceuticals until 2017. She has also extensive global and US experience from various senior positions in international pharmaceutical companies, including Smithkline Beecham, Bristol-Myers Squibb and Otsuka Pharmaceuticals.

Independent in relation to the Company’s major shareholders and the Company and its management.

Margarida Duarte

Board Member

BS in Pharmaceutical Sciences from Universidade de Lisboa and an Executive Master’s degree in Medical Marketing Management from Instituto Universitário de Lisboa.

Member of the Board since: 2025

Number of shares in Egetis: 0

Number of share awards in Egetis: 112,618

Born: 1976

Other current assignments: Senior Vice President, GM Europe & Emerging Markets, Genmab.

Previous appointments: Vice President, Head of Commercial Canada, Europe and Middle East and Africa for Alnylam Pharmaceuticals until 2021, launching Alnylam’s first products in rare disease. Ms. Duarte also has extensive global experience from various senior commercial positions in international pharmaceutical companies, including STEPSTONE Pharma, Exelixis, Onyx Pharmaceuticals and Amgen, with a focus in oncology and hematology and rare diseases.

Independent in relation to the Company’s major shareholders and the Company and its management.

Jay Donovan Wu

Board Member

MBA from the Stanford Graduate School of Business and BSEc in Finance and BA in Neurobiology from the University of Pennsylvania.

Member of the Board since: 2026

Number of shares in Egetis: 0

Number of share awards in Egetis: tba

Born: 1985

Other current assignments: Executive Vice President and President, Ascendis US where he oversees the US organization.

Previous appointments: Wu spent 2012–2025 at Genentech, with multiple leading positions, of which Vice President and Head of Rare Diseases as his latest. Before Genentech, Wu worked at Bain & Company focused on Healthcare and Private Equity.

Independent in relation to the Company’s major shareholders and the Company and its management.

Birgitte Volck

Board Member

Medical Doctor and Ph.D. in arthritis, both from Copenhagen University, Denmark.

Member of the Board since: 2026

Number of shares in Egetis: 0

Number of share awards in Egetis: tba

Born: 1962

Other current assignments: Strategic Advisor, OMass Therapeutics, Non Executive Director and chair, Nominating and Corporate Governance Committee Soleno Therapeutics and Consultant at BIVO.

Previous appointments: She has held senior research and development leadership roles in several global companies. Her latest operating role was at Ascendis Pharma during 2021–2023 as Executive Vice President & Interim Chief Medical Officer. Prior to Ascendis Pharma she served as President R&D at Avrobio Inc from 2018–2020. At GSK, 2016–2018, she was Senior Vice President Head of R&D, Rare Diseases. At SOBI, 2012–2016, she was CMO and SVP Development. From 2000 to 2012 she served in executive roles of increasing responsibility at Amgen, Genzyme and Pharmexa. Since 2016 Dr. Volck has served on a number of publicly listed biotechnology boards such as Wilson Therapeutics AB during 2017–2018 until the company was acquired by Alexion for USD 850 million.

Independent in relation to the Company’s major shareholders and the Company and its management.